Lung Cancer Trials Ask AI to find trials
TerminatedPhase 1NCT06466187
Official study title

A Study of SGN-MesoC2 in Advanced Solid Tumors

Study summary

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08052666/SGN-MesoC2. PF-08052666/SGN-MesoC2 is a type of antibody-drug conjugate (ADC). ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will have 3 parts. Part A and Part B of the study will find out how much PF-08052666/SGN-MesoC2 should be given to participants. Part C will use the information from Parts A and B to see if PF-08052666/SGN-MesoC2 is safe and if it works to treat solid tumor cancers.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedPF-08052666

The study team can explain what participation involves.

Who it may be forMesothelioma · Early-stage or resectable · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 7, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?19 U.S. locations

Locations may change over time.

Who runs it?Seagen, a wholly owned subsidiary of Pfizer

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Seagen, a wholly owned subsidiary of Pfizer
Interventions being studied
Drug: PF-08052666
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Mesothelioma→
Disease setting
Early-stage or resectable→Locally advanced→Metastatic or stage IV→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Aged 18 years or older.
  • Histologically- or cytologically-confirmed metastatic or locally advanced unresectable platinum-resistant ovarian cancer, NSCLC, pancreatic ductal adenocarcinoma, endometrial cancer, colorectal cancer, or mesothelioma, who have relapsed or progressed following standard therapies, or for which no standard therapies are available.
  • An Eastern Cooperative Oncology Group performance status score of 0 or 1.
  • At least 1 measurable lesion at baseline based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
  • Archival tumor tissue or a fresh tumor biopsy during the screening period.
  • Adequate hepatic, renal and bone marrow function.
  • Participants must not have received more than 2 lines of cytotoxic systemic therapy in the metastatic setting (Parts B and C only).
Reasons someone may not be able to joinExclusion criteria
  • Previously received or currently receiving any systemic anticancer therapy or focal radiotherapy within 4 weeks prior to the first dose of MesoC2 or within 2 weeks prior to the first dose of MesoC2 if the underlying disease had progressed on treatment.
  • Prior anti-MSLN antibody or MSLN-directed ADC (Part C only).
  • Unresolved toxicities from prior therapy greater than NCI CTCAE v5.0 grade 1 at the time of study treatment (except alopecia).
  • Inadequate hepatic dysfunction, renal function, or hematologic abnormalities.
  • Previously untreated brain metastases. Participants who received radiation or surgery for brain metastases are eligible if therapy was completed at least 4 weeks prior to study treatment initiation, and there was no evidence of central nervous system progression nor requirements for chronic corticosteroid therapy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of Alabama at BirminghamBirmingham, Alabama
  • The University of Alabama at BirminghamBirmingham, Alabama
  • University of Alabama at BirminghamBirmingham, Alabama
  • The Board of Trustees of the University of Alabama for the University of Alabama at BirminghamBirmingham, Alabama
  • The University of Kansas Clinical Research CenterFairway, Kansas
  • The University of Kansas Hospital Cambridge North Tower AKansas City, Kansas
  • The University of Kansas HospitalKansas City, Kansas
  • The University of Kansas Medical Center Medical Office BuildingKansas City, Kansas
  • The University of Kansas Cancer Center - Indian Creek CampusOverland Park, Kansas
  • The University of Kansas Cancer Center - WestwoodWestwood, Kansas
  • The University of Kansas Cancer Center, Investigational Drug ServicesWestwood, Kansas
  • Atrium Health Wake Forest BaptistWinston-Salem, North Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 7, 2026. Always confirm current availability with the study team.

View original record ↗